Product Information
CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB is a generic product labeled by ANI Pharmaceuticals, Inc., priced at $1.0778 per EA under NDC 62559066290. Its NADAC has been published 399 times since Feb 13, 2019.
FDA first approved this application on Sep 5, 2000. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB
Candesartan Cilexetil and HydrochlorothiazideStrength
32; 25 mg/1; mg/1
Manufacturer
ANI Pharmaceuticals, Inc.NDC
62559066290
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDEApproval Type
Authorized Generic (NDA)
FDA Application
NDA021093FDA Approved
9/5/2000
TE Code
AB
On Market Since
9/26/2018
Pharmacological Classes
Price Statistics
The NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB has been published 399 times since Feb 13, 2019, and over the history we have for it it has declined 73.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.0778 per EA |
|---|---|
| All-time high | $4.1187 (Mar 13, 2019) |
| All-time low | $0.9491 (Oct 22, 2025) |
| 52-week high | $1.2433 |
| 52-week low | $0.9491 |
| Median price | $1.6013 |
| Average price | $1.7019 |
| Largest weekly change | +149.4% (Apr 21, 2021) |
| Weeks tracked | 399 |
| Tracking since | Feb 13, 2019 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ANI Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Candesartan Cilexetil and Hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB, manufactured by ANI Pharmaceuticals, Inc., is $1.0778 per EA (NDC 62559066290), effective Sep 30, 2026.
How has the price of CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB changed over time?
Over the history we have for it, the NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB has declined 73.8%. It has been tracked across 399 weekly CMS publications since Feb 13, 2019.
What are the highest and lowest recorded NADAC prices for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB?
Since Feb 13, 2019, the NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB has ranged from a low of $0.9491 (Oct 22, 2025) to a high of $4.1187 (Mar 13, 2019), with a median of $1.6013 per EA.
Are there cheaper alternatives to CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB?
CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB (NDC 62559066290) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a generic product.